AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies ...

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV)In multiple preclinical models evaluated ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...

The following is a summary of “Continuum of light sensitivity in atopic dermatitis: A retrospective analysis of 139 cases in ...

Diagnosing and managing feline atopic dermatitis (FAD) can be difficult for clients, and can even be a challenge for ...